Clinical Trial Detail

NCT ID NCT04262375
Title A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University Health Network, Toronto
Indications

renal cell carcinoma

lung non-small cell carcinoma

Therapies

Durvalumab + Oleclumab

Age Groups: adult senior

Additional content available in CKB BOOST